Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 27.10
+0.92 (3.51%)
Nov 10, 2026, 4:08 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 9.53 billion as of November 9, 2026. It is the 8,972nd most valuable company in the world and the 447th biggest in Hong Kong. Its market cap has decreased by 40.38% in one year.
Market Cap
9.53B
Enterprise Value
9.47B
Revenue
2.78B
Global Rank
Country Rank
#447 Hong Kong
PE Ratio
n/a
ChartMarket Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 9.53B, a decrease of -53.83%. That is a compound annual growth rate of -11.92%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 10, 2026 | 9.53B | -27.07% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Metis TechBio | 13.35B |
| Ascentage Pharma Group International | 11.14B |
| Duality Biotherapeutics | 9.72B |
| HBM Holdings | 9.22B |
| GenFleet Therapeutics (Shanghai) | 9.01B |
| CStone Pharmaceuticals | 8.74B |
| Shaanxi Micot Pharmaceutical Technology | 7.95B |
| Suzhou Ribo Life Science | 7.66B |